Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

    NEXT STORY
    European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease
    PREV STORY
    Itamar Medical Appoints Scott P. Serota to its Board of Directors
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019

    author_avatar
    NASDAQ Market News

    Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark

    author_avatar
    NASDAQ Market News

    Conférence de presse de lundi de la conférence mondiale sur le cancer du poumon : résultats de la recherche clinique et différences entre les sexes pour la survie du cancer du poumon

    TORONTO, 26 sept. 2018 (GLOBE NEWSWIRE) -- Au cours de la conférence de presse ...

    author_avatar
    NASDAQ Market News